Relative Strength Index (RSI)
|Bid||351.00 x 900|
|Ask||355.51 x 1400|
|Day's Range||346.11 - 354.86|
|52 Week Range||196.78 - 380.76|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||55.92|
|Earnings Date||Apr 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||324.00|
Illumina, Inc. (NASDAQ: ILMN) is committed to supporting the global, national and local relief efforts of our customers, employees and communities, as we unite to combat COVID-19. Giving back is in our DNA, and together with the Illumina Corporate Foundation, we have committed more than $10M to support the communities where we live and work. As we champion the greater good, Illumina is focused on making sequencing accessible around the world to fight the pandemic together through the power of genomics, collaboration and global care for each other.
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing platforms, today announced that they have settled their patent infringement action ("Action") concerning Illumina's U.S. Patent No. 9,493,831 ("'831 Patent") and Natera's U.S. Patent No. 8,682,592 (the "'592 Patent"). Terms of the settlement are included in the Form 8-K filed May 11, 2020 by Natera with the U.S. Securities & Exchange Commission.
Simon Erickson of 7Investing.com joined the podcast this week to discuss the key metrics he uses to identify power growth stocks like Amazon and Tesla.
British researchers will study the genes of thousands of ill COVID-19 patients to try to crack one of the most puzzling riddles of the novel coronavirus: why does it kill some people but give others not even a mild headache? Researchers from across the United Kingdom will sequence the genetic code of people who fell critically ill with COVID-19 and compare their genomes with those who were mildly ill or not ill at all. The hunt for the specific genes that could cause a predisposition to getting ill with COVID-19 will involve up to 20,000 people currently or previously in hospital intensive care with COVID-19 and about 15,000 people with mild symptoms.
Earlier today, we issued a press release outlining the financial results we will be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or alternatively as furnished on the Form 8-K available on the Securities and Exchange Commission website at www.sec.gov. With me today are Mike Hunkapiller, our Chief Executive Officer; Susan Barnes, our Chief Financial Officer; and Ben Gong, our Vice President of Finance and Treasurer.
The "ImmuneRace" study will genetically map the T-cells of 1,000 people who have been exposed to SARS-CoV-19.
Australia says its purchase of 10 million coronavirus test kits from Chinese genomics company BGI will not risk patient privacy, as researchers hope for greater price competition in a biotech market dominated by a U.S rival. The deal was struck even as relations between Australia and China have been strained by Australia's call for a global enquiry into the coronavirus outbreak, which China has framed as a U.S.-led attempt to blame it for the pandemic. BGI – Beijing Genomics Institute - has grown into one of the world's largest genomics companies in the two decades since it worked on the Human Genome Project.
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development functions and the innovation engine for next-generation sequencing platforms and applications, accelerating technology breakthroughs and translation to the clinic. Dr. Aravanis will join Illumina in early June and will report to Chief Executive Officer, Francis deSouza. Mostafa Ronaghi, who served as Illumina’s Chief Technology Officer, is taking on a new role as Senior Vice President of Entrepreneurial Development, responsible for supporting and catalyzing the expanding genomics entrepreneurial ecosystem.
Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.
Illumina (ILMN) delivered earnings and revenue surprises of 30.16% and 0.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.
Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation of our sequencing systems and related consumables intended to expand SARS-CoV-2 sequencing capabilities and capacity in ten African countries, including the Democratic Republic of the Congo, Egypt, Ethiopia, Ghana, Kenya, Mali, Nigeria, Senegal, South Africa and Uganda.
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using next-generation sequencing (NGS). The toolkit makes it easier for researchers to detect and identify the SARS-CoV-2 viral sequence in their samples and contribute their findings to critical public databases. Illumina is making the toolkit available at no cost to the global research community in support of efforts to combat the pandemic.
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The number of U.S. cases of the coronavirus that causes COVID-19 rose above 610,000 on Wednesday, as President Donald Trump suspended funding to the World Health Organization, drawing criticism from other world leaders and health officials during the middle of the pandemic.